biotech.today

Details

  • ●Modalities: small molecules, CRISPR/gene editing, cell therapy
  • ●Therapeutic areas: cystic fibrosis, pain, hematology, nephrology, type 1 diabetes
  • ●Key targets: CFTR, NaV1.8, NaV1.7, APOL1, stem cell-derived islets
  • ●Indications: cystic fibrosis, sickle cell disease, transfusion-dependent beta-thalassemia, acute pain
  • ●Funding: N/A (public since 1991, ~$12B annual revenue)

Partners & investors

  • Public (NASDAQ: VRTX)· Investor

Key considerations

  • ●AI tools in use: Genomics plc partnership (ML + human genetics), Internal computational chemistry platform, Structural biology / cryo-EM pipeline
  • ●Genomics plc collaboration extended for ML-driven target discovery
  • ●Computational approaches integrated across drug design pipeline
  • ●$12B+ annual revenue (2025) funds large internal R&D infrastructure

Pipeline

  • Approved2
Get live updates on Vertex Pharmaceuticals’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Reshma Kewalramani

CEO & President

nephrologyclinical developmentcorporate strategy

David Altshuler

Chief Scientific Officer & EVP

human geneticsgenomicstranslational medicine
Visit website →LinkedIn →